A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials

Scientific Data

Volumn 3, Issue , 2016, Pages

  Geifman, N ^a   Butte, A J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DOCETAXEL; GONADORELIN; MITOXANTRONE; PREDNISONE; TAXOID;

CLINICAL TRIAL (TOPIC); HUMAN; MALE; META ANALYSIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PROSTATIC NEOPLASMS; STANDARDS; SURVIVAL RATE; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MITOXANTRONE; PREDNISONE; PROSTATIC NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 84966350750     PISSN: None     EISSN: 20524463     Source Type: Journal    
DOI: 10.1038/sdata.2016.27     Document Type: Article

References (36)

1. Jemal, A. et al. Global cancer statistics. CA: A cancer journal for clinicians 61, 69-90 (2011).
2. Hanks, G. E., Hanlon, A. L., Epstein, B. & Horwitz, E. M. Dose response in prostate cancer with 8-12 years' follow-up. International journal of radiation oncology, biology, physics 54, 427-435 (2002).
3. Freedland, S. J. et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama 294, 433-439 (2005).
4. Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360, 103-106 (2002).
5. Pilepich, M. V. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. International journal of radiation oncology, biology, physics 61, 1285-1290 (2005).
6. Crawford, E. D. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. The New England journal of medicine 321, 419-424 (1989).
7. Sharifi, N., Gulley, J. L. & Dahut, W. L. Androgen deprivation therapy for prostate cancer. Jama 294, 238-244 (2005).
8. Denmeade, S. R. & Isaacs, J. T. A history of prostate cancer treatment. Nature reviews. Cancer 2, 389-396 (2002).
9. Eisenberger, M. A. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. The New England journal of medicine 339, 1036-1042 (1998).
10. Green, A. K. et al. The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data. The oncologist 20, 464-e20 (2015).
11. Hede, K. Project data sphere to make cancer clinical trial data publicly available. Journal of the National Cancer Institute 105, 1159-1160 (2013).
12. Nisen, P. & Rockhold, F. Access to patient-level data from GlaxoSmithKline clinical trials. The New England journal of medicine 369, 475-478 (2013).
13. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine 351, 1502-1512 (2004).
14. Mohler, J. et al. NCCN clinical practice guidelines in oncology: prostate cancer. Journal of the National Comprehensive Cancer Network: JNCCN 8, 162-200 (2010).
15. Green, A. K. et al. Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrateresistant prostate cancer after docetaxel failure. The oncologist 20, 516-522 (2015).
16. Tannock, I. F. et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 14, 1756-1764 (1996).
17. Tannock, I. et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 7, 590-597 (1989).
18. Osoba, D., Tannock, I. F., Ernst, D. S. & Neville, A. J. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17, 1654-1663 (1999).
19. Kantoff, P. W. et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17, 2506-2513 (1999).
20. Moore, M. J. et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 12, 689-694 (1994).
21. Gomella, L. G. Effective testosterone suppression for prostate cancer: is there a best castration therapy> Reviews in urology 11, 52-60 (2009).
22. Byar, D. P. Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. Bulletin of the New York Academy of Medicine 48, 751-766 (1972).
23. Blackard, C. E., Byar, D. P. & Jordan, W. P. Jr. Orchiectomy for advanced prostatic carcinoma. A reevaluation. Urology 1, 553-560 (1973).
24. Hussain, M., Wolf, M., Marshall, E., Crawford, E. D. & Eisenberger, M. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 12, 1868-1875 (1994).
25. Potosky, A. L. et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 19, 3750-3757 (2001).
26. Clark, J. A., Wray, N. P. & Ashton, C. M. Living with treatment decisions: regrets and quality of life among men treated for metastatic prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 19, 72-80 (2001).
27. Samson, D. J. et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95, 361-376 (2002).
28. Krumholz, H. M. & Peterson, E. D. Open access to clinical trials data. Jama 312, 1002-1003 (2014).
29. Lo, B. Sharing clinical trial data: maximizing benefits, minimizing risk. Jama 313, 793-794 (2015).
30. Rosenblatt, M., Jain, S. H. & Cahill, M. Sharing of clinical trial data: benefits, risks, and uniform principles. Annals of internal medicine 162, 306-307 (2015).
31. Ross, J. S., Lehman, R. & Gross, C. P. The importance of clinical trial data sharing: Toward more open science. Circulation. Cardiovascular quality and outcomes 5, 238-240 (2012).
32. National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease. in Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease (National Academies Press, 2011).
33. Chawla, N. V. & Davis, D. A. Bringing big data to personalized healthcare: A patient-centered framework. Journal of general internal medicine 28 Suppl 3, S660-S665 (2013).
34. Shaikh, A. R. et al. Collaborative biomedicine in the age of big data: The case of cancer. Journal of medical Internet research 16, e101 (2014).
35. American Joint Committee on Cancer. in Cancer Staging Manual, 6th edn, 309-316 (Springer, 2002).
36. A Package for Survival Analysis in S. v. 2. 38. https://cran. r-project. org/package=survival (2015).